EconPapers    
Economics at your fingertips  
 

A state-of-the-art multi-criteria model for drug benefit-risk analysis

H.L. Hillege, E. Buskens, D. Postmus and T. Tervonen
Additional contact information
T. Tervonen: Groningen University

No 10001, Research Report from University of Groningen, Research Institute SOM (Systems, Organisations and Management)

Abstract: Drug benefit-risk analysis is based on firm clinical evidence related to various safety and efficacy outcomes, such as tolerability, treatment response, and adverse events. In this paper, we propose a new approach for constructing a supporting multi-criteria model that fully takes into account this evidence. Our approach is based on the Stochastic Multicriteria Acceptability Analysis (SMAA) methodology, which allows us to compute the typical value judgments that support a decision, to quantify uncertainty, and to compute a comprehensive benefit-risk profile. As an example, we constructed a multi-criteria model for the therapeutic group of second-generation antidepressants. We analyzed Fluoxetine, Paroxetine, Sertraline, and Venlafaxine according to relative efficacy and absolute rates of several common adverse drug reactions using meta-analytical data from the literature. Our model showed that there are clear trade-offs among the four drugs. Based on our experiences from this study, SMAA appears to be a suitable approach for quantifying trade-offs and decision uncertainty in drug benefit-risk analysis.

Date: 2010
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/11370/f8221a93-19fd-4aee-8ae3-fb98470d893c (application/pdf)
Our link check indicates that this URL is bad, the error code is: 403 Forbidden (http://hdl.handle.net/11370/f8221a93-19fd-4aee-8ae3-fb98470d893c [302 Found]--> https://research.rug.nl/en/publications/f8221a93-19fd-4aee-8ae3-fb98470d893c [301 Moved Permanently]--> https://research.rug.nl/en/publications/a-state-of-the-art-multi-criteria-model-for-drug-benefit-risk-ana)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gro:rugsom:10001

Access Statistics for this paper

More papers in Research Report from University of Groningen, Research Institute SOM (Systems, Organisations and Management) Contact information at EDIRC.
Bibliographic data for series maintained by Hanneke Tamling ().

 
Page updated 2025-03-30
Handle: RePEc:gro:rugsom:10001